Background/Aims: An updated systematic review and meta-analysis was conducted to assess the effect of prophylactic dexamethasone for tracheal intubation of general anesthesia on postoperative sore throat (POST). Methods: Comprehensive literature search of databases for randomized controlled trials (RCTs), including Embase, PubMed, and Cochrane Library, which evaluate the effect of prophylactic dexamethasone on POST was conducted. RevMan 5.0 and STATA 12.0 software were used to perform meta-analyses. Results: Fourteen RCTs totaling 1,837 patients were included for analysis. Compared with placebo, a significant reduction in the incidence of POST (OR 0.44, 95% CI 0.33-0.58, P<0.00001), hoarseness (OR 0.42, 95% CI 0.31-0.58, P<0.00001), and postoperative nausea and vomiting (PONV) (OR 0.06, 95% CI 0.03-0.14, P<0.00001) and a comparable incidence of cough (OR 0.59, 95% CI 0.19-1.89, P=0.38) was described in patients receiving dexamethasone, with or without concomitant drugs. Dexamethasone ≥0.2 mg/kg had a statistically greater impact on reducing the incidence of POST than dexamethasone 0.1-0.2 mg/kg, while dexamethasone ≤0.1 mg/kg did not. Dexamethasone was as effective as other drugs such as ondansetron, magnesium sulfate, ketamine gargle, betamethasone gel, and ketorolac for reducing POST (OR 0.70, 95% CI 0.46-1.07, P=0.10). Dexamethasone plus a different drug was more effective than dexamethasone alone for reducing the incidence of POST at 24 hours (OR 0.40, P=0.006). Compared with controls, a statistically higher blood glucose level was the only adverse event during the immediate postoperative period in patients receiving dexamethasone. Conclusions: Intravenous dexamethasone ≥0.2 mg/kg within 30 minutes before or after induction of general anesthesia should be recommended as grade 1A evidence with safety and efficacy in reducing the incidence of POST, hoarseness, and PONV in patients without pregnancy, diabetes mellitus, or contraindications for corticosteroids.
Introduction
Postoperative sore throat (POST) is common after tracheal intubation of general anesthesia. Numerous factors including age, female gender, smoking history, size of the endotracheal tube, cuff pressure, time and manipulations needed to insert the tube, and time of operation and anesthesia may affect the incidence of POST, with discomfort and dissatisfaction.
A previous systematic review and meta-analysis has demonstrated a significant reduction in the incidence of POST from intubation at 24 hours in patients treated with intravenous dexamethasone compared with placebo, 7 with similar results as another one. 8 However, the relatively small sample size included in both the reviews precluded the authors from drawing definitive conclusions, and the optimal timing of dexamethasone administration, and combination effect of dexamethasone with other medicines, remains unclear.
Therefore, we conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the impact of prophylactic dexamethasone on POST for tracheal intubation of general anesthesia.
Methods
Our systematic review and meta-analysis was reported according to the recommendations of the PRISMA statement. 9 
Outcome measures
The incidence of POST during the immediate 24-hour postoperative period was defined as primary endpoint, while the incidence of hoarseness, postoperative nausea and vomiting (PONV), cough, and adverse events were defined as secondary endpoints.
Data collection and analysis
Keywords were searched in Embase, PubMed, and Cochrane Library from their inception to December 12, 2017 . RCTs were further identified by Cochrane Highly Sensitive Search Strategies. 10 Keywords and MeSH terms were used in combination as follows: 1) corticosteroid, glucocorticoid, steroid, or dexamethasone; AND 2) sore throat, or sore throats, as shown in Table S1 . Additional studies were identified by searching Authors' names, "related articles" function, and screening the reference lists.
Section criteria
RCTs written in the English language assessing the prophylactic impact of dexamethasone vs placebo without other antiemetics, dexamethasone vs placebo plus concomitant administration of a different drug, dexamethasone vs a different drug, dexamethasone plus a different drug vs dexamethasone, or comparisons using different doses of dexamethasone for POST in patients with tracheal intubation of general anesthesia undergoing surgery except tonsillectomy were included. Exclusion criteria were as follows: 1) non-RCTs; 2) studies including patients undergoing tonsillectomy or laryngeal surgery; 3) studies without available data; 4) overlapping data; or 5) letters, reviews, case reports, and expert opinions.
Data extraction and management
The information and data we obtained were extracted from included studies by by Yaofei Jiang and Ruoxi Chen, and a third investigator was used to judge any disagreements. For each study, we recorded information and data of study population, interventions, and outcomes.
Assessment of quality of evidence in included studies
Cochrane risk of bias instrument was used to assess the risk of bias for RCT quality by two reviewers independently.
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The following six items were examined including sequence generation, allocation concealment, double-blind evaluation, completeness of outcome data, selective reporting of outcome, and comparability of baseline characteristics between groups. The bias risk for each item was classified as high, low, or unclear. RCTs with no less than three items defined as high risk of bias were excluded for the meta-analysis. The seven matching criteria used to assess the baseline comparability between groups were as follows: age, gender, weight or BMI, American Society of Anaesthesiologists (ASA), intubation attempts, time of operation, and time of anesthesia. We defined baseline as incomparability if the number of nonmatching criteria was no less than 3.
Statistical analysis
RevMan 5.0 and STATA 12.0 software were used to perform statistical analyses. Dichotomous variables were calculated with ORs and 95% CIs. We used random-effects model to pool data with statistical heterogeneity determined by the inconsistency index (I 2 ≥50%) and the Chi-squared test (P≤0.10). Subgroup analyses were conducted to determine the optimal dose and administration time. Sensitivity analyses were performed by omitting one study at a time. Begg's rank correlation test was used to assess the publication bias, determined as positive by Pr>|z|≤0.1. 12 The overall quality of evidence from available RCTs was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.
Characteristics of included studies
The characteristics of the studies included are shown in Table 1 . Fourteen RCTs totaling 1,837 patients undergoing general anesthesia with tracheal intubation were included.
Patients classified as ASA class I or II were included in majority of the RCTs. Exclusion criteria were as follows: pregnancy, diabetes mellitus, obesity, and any contraindication to corticosteroid medications. Dexamethasone ranging from 4 to 0.2 mg/kg was administered intravenously in single or combination except one RCT 15 administered locally. Timing of dexamethasone administration varied from 30 minutes 19 and ketorolac 20 or a combination of these medications. Regarding the methodological quality of the RCTs, all showed low overall risks of bias (Table 2 ).
Treatment effects
Primary endpoints incidence of POST: dexamethasone vs placebo, with or without concomitant drugs
The incidence of POST comparing dexamethasone vs placebo with or without concomitant drugs was reported in nine trials. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Compared with placebo, a statistical decrease in the incidence of POST at 24 hours was found in patients treated with dexamethasone, with or without concomitant drugs (OR 0.44, 95% CI 0.33-0.58, P<0.00001; Figure 2 19 or ketorolac, 20 was described in five RCTs. Compared with these different drugs, no statistical difference in the incidence of POST at 24 hours was found in patients receiving dexamethasone (OR 0.70, 95% CI 0.46-1.07, P=0.10; Figure 3 ). No statistical heterogeneity was found among studies (P=0.49, I 2 =0%). incidence of POST: dexamethasone plus a different drug vs dexamethasone Data on incidence of POST comparing dexamethasone plus a different drug vs dexamethasone were reported in three trials. 16, 18, 26 Compared with dexamethasone, a statistical decrease in the incidence of POST at 24 hours was found in patients treated with dexamethasone plus a different drug (OR 0.40, 95% CI 0.21-0.77, P=0.006; Figure 4 ). No statistical heterogeneity was found among studies (P=0.24, I 2 =31%).
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Prophylactic dexamethasone on postoperative sore throat Secondary endpoints incidence of hoarseness: dexamethasone vs placebo, with or without concomitant drugs The incidence of hoarseness was reported in six RCTs. 15, 17, 18, 20, 24, 25, 27 Compared with placebo, a significant reduction in the incidence of hoarseness was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.42, 95% CI 0.31-0.58, P<0.00001; Figure 5 ). No statistical heterogeneity was found among studies (P=0.16, I 2 =32%). 
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Prophylactic dexamethasone on postoperative sore throat incidence of PONv: dexamethasone vs placebo, with or without concomitant drugs The incidence of PONV was described in five RCTs. 16, [20] [21] [22] 27 Compared with placebo, a significant reduction in the incidence of PONV was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.06, 95% CI 0.03-0.14, P < 0.00001; Figure 6 ). No statistical heterogeneity was found among studies (P=0.19, I 2 =35%).
incidence of cough: dexamethasone vs placebo, with or without concomitant drugs The incidence of cough was reported in three RCTs. 19, 25, 27 Compared with placebo, comparable incidence of cough was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.59, 95% CI 0.19-1.89, P=0.38; Figure 7 ). Statistical heterogeneity was found among studies (P=0.02, I 2 =71%). incidence of adverse events: dexamethasone vs placebo with or without concomitant drugs Data on postoperative blood glucose in patients receiving dexamethasone were described in one RCT. 17 Compared with magnesium sulfate, statistically higher level of postoperative blood glucose was described in patients treated with dexamethasone. Compared with controls, comparable incidence of other adverse events such as dysphonia, dysphagia, itching, wound infection, diarrhea, headache, muscle pain, dizziness, drowsiness, urinary retention, and abdominal distension was found in patients treated with dexamethasone.
Subgroup analyses incidence of POST: dose of dexamethasone
Subgroup analyses according to the dose of dexamethasone ranging from 4 to 0.2 mg/kg indicated that dexamethasone ≥0.2 mg/kg and 0.1-0.2 mg/kg both significantly reduced Figure S1 .
incidence of POST: timing of dexamethasone administration Patients in most of the trials were administered with dexamethasone that varied from 30 minutes to immediately before induction of anesthesia. The incidence of POST in patients treated with dexamethasone administered 30 minutes prior to intubation vs 30 minutes after tracheal intubation was described in two RCTs. 28, 29 Figure S2 ). No statistical heterogeneity was found among studies (P=0.66, I 2 =0%).
Sensitivity analysis
Sensitivity analyses omitting one study at a time demonstrated a significantly different result of meta-analysis on 
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Prophylactic dexamethasone on postoperative sore throat POST incidence comparing dexamethasone with a different drug.
Publication bias
No statistical publication bias was found among studies by Begg's rank correlation test, except for the data on POST incidence in patients treated with dexamethasone vs placebo, with or without concomitant drugs (Pr>|z|=0.008) ( Table S2 ).
Quality of evidence
As shown in Table 3 , quality of GRADE evidence from available RCTs, upgraded by large-effect or dose-response gradient, and downgraded by publication bias (Pr>|z|≤0.1), indirectness (variations in study setting), imprecision (sensitivity analysis with a significantly different conclusion), or inconsistency (statistical heterogeneity among studies). ⊕⊕⊝⊝ low j *The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% Ci) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% Ci). GRADe working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate. Reliability and conclusiveness of composite outcome result For conclusive and reliable meta-analysis, we calculated the optimal sample size by assuming a 40% control event rate of POST and a 25% relative risk reduction with 80% power and a two-sided a=0.01. Our calculations with sequential monitoring boundary crossing indicated that the cumulative evidence is reliable and conclusive ( Figure S3 ).
Discussion
For patients experiencing tracheal intubation of general anesthesia, POST is a common but unpleasant complication. As glucocorticoid, dexamethasone has anti-inflammatory and analgesic impact. Therefore, prophylactic dexamethasone may be beneficial.
Our study demonstrated the safety and efficacy of prophylactic dexamethasone for patients undergoing sur-gery requiring tracheal intubation of general anesthesia in reducing the incidence of POST, hoarseness, and PONV compared with placebo, with or without contaminant drugs. It may be explained that dexamethasone is antiinflammatory and immunosuppressive agent, and it may exert its therapeutic actions through central inhibition of prostaglandin synthesis, by decreasing serotonin turnover in the central nervous system, and by influencing the systemic inflammatory response in favor of anti-inflammatory mediators. 5, 6, 30 Besides, our meta-analysis demonstrated comparable efficacy of dexamethasone in reducing POST as other drugs including ondansetron, magnesium sulfate, ketamine gargle, betamethasone gel, and ketorolac in this patient population. Among these latter, ondansetron exerts positive effects on pain relief as a Na channel blocker, a 5-HT3 receptor antagonist, and μ-opioid agonist, 31 while magnesium sulfate 32, 33 and ketamine gargle 34 both as N-methyl-d-aspartate (NMDA) receptor antagonists, betamethasone gel as corticosteroids, and ketorolac as an NSAID with analgesic and anti-inflammatory activities by inhibiting cyclooxygenase. Dexamethasone in combination with other drugs is most effective in reducing POST, perhaps due to its synergistic effects of pain relief through NMDA receptor antagonists. 34, 35 Although without other serious adverse events, dexamethasone was associated with increased level of postoperative blood glucose.
To determine the optimal dose of dexamethasone, subgroup analyses stratified by dose indicated more efficacies of higher doses of dexamethasone (≥0.2 mg/kg) compared with lower doses (0.1-0.2 mg/kg). In almost all trials included, dexamethasone was administered that varied from 30 minutes before tracheal intubation to 30 minutes after tracheal intubation. One of the concerns of dexamethasone administration is the potential for poor glycemic control. Postoperative glucose level measured at immediate postoperative period was higher in the dexamethasone group, as described by Park et al. 17 Considering the results of the evaluated blood glucose, magnesium sulfate could be a valuable option in the prevention of POST when the use of dexamethasone may not be appropriate for its potential side effects.
Several limitations still exist in this meta-analysis. First, statistical heterogeneity on postoperative cough was found among studies, while publication bias was found on POST. Second, the RCTs in this meta-analysis mostly included healthy patients and excluded patients with pregnancy, diabetes mellitus, or contraindications for corticosteroids. Therefore, the prophylactic impact of dexamethasone on these patients is still unknown.
Conclusion
Our meta-analysis demonstrated safety and efficacy of prophylactic dexamethasone in reducing the incidence of POST, hoarseness, and PONV in patients requiring tracheal intubation of general anesthesia compared with placebo, with or without concomitant drugs. Prophylactic dexamethasone ≥0.2 mg/kg administered intravenously within 30 minutes before or after induction of general anesthesia should be recommended as grade 1A evidence with safety and efficacy for patients without pregnancy, diabetes mellitus, or contraindications for corticosteroids. 
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